insights_auto
Why is MVIR up २.३३%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEK १.४९
arrow_upward
+२.३३%(+०.०३४) 1D
अक्टोबर ९, १७:२९:४२ GMT+२ · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEK १.४७
High
SEK १.५०
Low
SEK १.४५
Mkt. cap
९३.२५ करोड
Avg. vol.
१४.१३ लाख
Volume
१७.३२ लाख
52-wk high
SEK २.८८
52-wk low
SEK ०.३४
EPS
-SEK ०.३७
Shares outstanding
६२.४२ करोड
No. of employees
६
Open
SEK १.४७
High
SEK १.५०
Low
SEK १.४५
Mkt. cap
९३.२५ करोड
Avg. vol.
१४.१३ लाख
Volume
१७.३२ लाख
52-wk high
SEK २.८८
52-wk low
SEK ०.३४
EPS
-SEK ०.३७
Shares outstanding
६२.४२ करोड
No. of employees
६
News stories
From web sources and news partners
Yahoo Finance
·
३७ मिनेट पहिले
Wall Street split on pioneering S&P 500 stock's price target
Benzinga
·
११ मिनेट पहिले
S&P 500 Earnings Preview: Will Strong Profits Fuel the Next Rally?
Kalkine Media
·
४३ मिनेट पहिले
Why Does Strategy (NASDAQ:MSTR) Matter After the Rebound?
Seeking Alpha
·
३ घण्टा पहिले
The 1-Minute Market Report October 10, 2026 (NYSEARCA:VOO)
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB